Duality Advisers, LP Corcept Therapeutics Inc Transaction History

Duality Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$21.1 - $27.46 $1.63 Million - $2.12 Million	77,346 Added 653.15%	89,188 $2.25 Million
Q4 2023 Feb 01, 2024	BUY	$24.82 - $32.88 $6,775 - $8,976	273 Added 2.36%	11,842 $384,000
Q3 2023 Nov 02, 2023	SELL	$21.97 - $33.8 $490,458 - $754,551	-22,324 Reduced 65.87%	11,569 $315,000
Q2 2023 Jul 31, 2023	BUY	$21.44 - $25.15 $726,665 - $852,408	33,893 New	33,893 $754,000
Q4 2022 Feb 07, 2023	BUY	$19.95 - $29.96 $675,806 - $1.01 Million	33,875 Added 193.2%	51,409 $1.04 Million
Q3 2022 Nov 03, 2022	BUY	$24.7 - $29.12 $433,089 - $510,590	17,534 New	17,534 $450,000

346

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.51B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.